Efficacy News and Research

RSS

‘Real-world’ sunitinib findings support trial results

Results of postmarketing follow-up in Japanese patients confirm the efficacy and safety profile of sunitinib in advanced renal cell carcinoma.

29 May 2015

New clinical data demonstrating treatment options in Lilly's diabetes portfolio to be presented at ADA Scientific Sessions

New clinical data demonstrating the range of treatment options represented in Lilly's diabetes portfolio will be presented in 79 abstracts on June 5-9, at the 75th American Diabetes Association (ADA)® Scientific Sessions in Boston.

29 May 2015

Measuring kidney function and damage may help predict people at risk for heart disease

Simple measures of kidney function and damage may be just as good at predicting who is at risk for heart failure and death from heart attack and stroke as traditional tests of cholesterol levels and blood pressure, new Johns Hopkins Bloomberg School of Public Health-led research suggests.

29 May 2015

Can-Fite BioPharma reports Q1 2015 financial results, provides updates on drug development programs

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the three months ended March 31, 2015 and updates on its drug development programs.

29 May 2015

DDW 2015: Experts explore efficacy of Stretta therapy for treating chronic GERD patients

A special presentation at Digestive Disease Week 2015 featured GERD experts weighing in on their successful experience using Stretta therapy to treat challenging patient populations suffering from GERD.

29 May 2015

Amgen announces AMG 416 Phase 3 results for treatment of secondary hyperparathyroidism in CKD patients

Amgen today announced pooled data from two pivotal Phase 3, global, randomized, placebo-controlled trials evaluating AMG 416, a novel calcimimetic, for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (CKD) receiving hemodialysis.

29 May 2015

Study explores efficacy of selective serotonin reuptake inhibitors in reducing depressed mood

Many have recently questioned the efficacy of the most common antidepressant medications, the selective serotonin reuptake inhibitors (SSRIs). The conclusion that these drugs are ineffective is however partly based on a misinterpretation of the outcome of the clinical trials once conducted to demonstrate their efficacy. This was the finding of a study conducted by researchers at the Sahlgrenska Academy.

29 May 2015

Lilly Diabetes Alliance, Boehringer Ingelheim to present study results at ADA’s Scientific Sessions

The presentation of 35 abstracts will demonstrate the breadth and depth of the Boehringer Ingelheim and Eli Lilly and Company Diabetes alliance portfolio at the 75th American Diabetes Association's (ADA) Scientific Sessions® in Boston, June 5-9.

29 May 2015

MEDI4736 and tremelimumab combination shows acceptable safety, potential efficacy in NSCLC patients

Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and potential efficacy when used as single-agents in several different types of cancer.

29 May 2015

JAK2 inhibitor ruxolitinib shows promise in treating CMML patients

Chronic myelomonocytic leukemia (CMML) is a rare type of myelodysplastic, myeloproliferative neoplasm characterized by increased numbers of peripheral monocytes and less than 20 percent blasts. CMML has few treatment options and patients only survive on average for 12 to 24 months.

29 May 2015

PDS Biotechnology announces positive results from PDS0101 Phase I trial in pre-cervical cancer patients

PDS Biotechnology Corp. announces preliminary data showing that PDS0101, a cancer immunotherapy treatment targeting HPV-16, has generated strong T-cell responses in pre-cervical cancer patients.

28 May 2015

Data supporting anti-cancer potential of Biscayne’s GHRH antagonist to be discussed at ASCO Annual Meeting

Biscayne Pharmaceuticals, Inc., today announced that data supporting the anti-cancer potential of its growth hormone-releasing hormone (GHRH) technology will be discussed in a poster presentation at the 2015 ASCO Annual Meeting.

28 May 2015

3-D imaging technique may be useful for measuring efficacy of injectable wrinkle reducers

A three-dimensional imaging technique often used in the automotive and aerospace industries for accurate measurement may be useful to measure the efficacy of injectable wrinkle reducers such as Botox and Dysport, according to new research from the Perelman School of Medicine at the University of Pennsylvania.

28 May 2015

Salix Pharmaceuticals receives FDA approval for Xifaxan 550 mg to treat IBS-D in adults

Valeant Pharmaceuticals International, Inc. announced that its wholly owned subsidiary, Salix Pharmaceuticals, Inc., has received approval from the U.S. Food and Drug Administration for Xifaxan 550 mg for the treatment of IBS-D in adults.

28 May 2015

GnRH infusion recommended for adolescent hypogonadotropic hypogonadodism

Pulsatile gonadotropin-releasing hormone may be more effective than human chorionic gonadotropin for the treatment of peripubescent boys with hypogonadotropic hypogonadodism, say Chinese researchers.

27 May 2015

Positive clinical data of CytRx's aldoxorubicin to be presented at ASCO 2015

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced an upcoming poster presentation regarding its lead drug candidate, aldoxorubicin, at the 2015 American Society of Clinical Oncology Annual Meeting, which is being held May 29 - June 2, 2015 in Chicago.

27 May 2015

Six research teams awarded grant to accelerate discovery of new drugs for brain, nervous system disorders

CQDM, Brain Canada and the Ontario Brain Institute award close to $8.5M to six (6) multi-disciplinary and multi-provincial research teams across Canada to address unmet needs in neuroscience within their Focus on Brain strategic initiative. To this amount, $1.5M is added from the various research entities involved as in-kind contributions.

27 May 2015

$Brittle bones does not significantly affect occurrence of bone fractures among older people$

Brittle bones does not significantly affect occurrence of bone fractures among older people

Anti-osteoporotic medication is not an effective means for preventing hip fractures among the elderly, concludes a study recently published in the BMJ. According to Professor Teppo Järvinen from the University of Helsinki, who heads the research group, the prevalent assumption that brittle bones cause hip fractures is fundamentally flawed.

27 May 2015

New stem-cell based therapy provides pain relief, reduces severity of RDEB in children

Promising results from a trial of a new stem-cell based therapy for a rare and debilitating skin condition have been published in the Journal of Investigative Dermatology. The therapy, involving infusions of stem cells, was found to provide pain relief and to reduce the severity of this skin condition for which no cure currently exists.

27 May 2015

New Health Union study finds severe impact of rheumatoid arthritis on patients' quality of life

In a new national survey of rheumatoid arthritis (RA) patients, Health Union found a severe impact on quality of life, employment, and ability to afford treatment. The autoimmune condition attacks the body, resulting in joint inflammation, pain, stiffness, and swelling, but may also harm other organs. About 1.3 million Americans or about one percent of the global population have RA.

27 May 2015

Efficacy News and Research

‘Real-world’ sunitinib findings support trial results

New clinical data demonstrating treatment options in Lilly's diabetes portfolio to be presented at ADA Scientific Sessions

Measuring kidney function and damage may help predict people at risk for heart disease

Can-Fite BioPharma reports Q1 2015 financial results, provides updates on drug development programs

DDW 2015: Experts explore efficacy of Stretta therapy for treating chronic GERD patients

Amgen announces AMG 416 Phase 3 results for treatment of secondary hyperparathyroidism in CKD patients

Study explores efficacy of selective serotonin reuptake inhibitors in reducing depressed mood

Lilly Diabetes Alliance, Boehringer Ingelheim to present study results at ADA’s Scientific Sessions

MEDI4736 and tremelimumab combination shows acceptable safety, potential efficacy in NSCLC patients

JAK2 inhibitor ruxolitinib shows promise in treating CMML patients

PDS Biotechnology announces positive results from PDS0101 Phase I trial in pre-cervical cancer patients

Data supporting anti-cancer potential of Biscayne’s GHRH antagonist to be discussed at ASCO Annual Meeting

3-D imaging technique may be useful for measuring efficacy of injectable wrinkle reducers

Salix Pharmaceuticals receives FDA approval for Xifaxan 550 mg to treat IBS-D in adults

GnRH infusion recommended for adolescent hypogonadotropic hypogonadodism

Positive clinical data of CytRx's aldoxorubicin to be presented at ASCO 2015

Six research teams awarded grant to accelerate discovery of new drugs for brain, nervous system disorders

Brittle bones does not significantly affect occurrence of bone fractures among older people

New stem-cell based therapy provides pain relief, reduces severity of RDEB in children

New Health Union study finds severe impact of rheumatoid arthritis on patients' quality of life

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News